We use a unique science-driven approach to engineer endolysins and antimicrobial vectors into targeted antibacterial treatments, leveraging the high potential of both technologies for our proprietary products.

Engineering Endolysins

We create endolysins optimized for specific and effective treatments using advanced molecular engineering techniques. Our molecules selectively target harmful bacteria – including resistant strains – which cause and exacerbate acute and chronic illnesses. The natural bacteria of the microbiome, beneficial for our health, remain unaffected. Due to the unique mode of action of endolysins, there is a very low propensity for resistance development.

Engineering Antimicrobial Vectors

Our engineered antimicrobial vector technology is leveraging the genetic scaffold of bacteriophages to engineer novel and patentable precision antimicrobials as a new class of biologics for the treatment of  bacterial infections.

Our state-of-the art Drug Discovery unit for endolysins and antimicrobial vectors is based in Zurich, Switzerland.

Application of Engineered Endolysins

Micreos is bringing engineered endolysin-based treatments to patients suffering from diseases that are caused or aggravated by pathogenic bacteria. This approach is currently being applied to two therapeutic areas: Cutaneous T-cell Lymphoma (CTCL) and Atopic Dermatitis (AD)

CTCL header

Cutaneous T-cell Lymphoma (CTCL)

Colonization of the skin with Staphylococcus aureus (S. aureus) has a dual effect on patients with cutaneous T-cell lymphoma (CTCL) contributing to skin symptoms and also proliferation of malignant T-cells and disease progression.

CTCL has a profound impact on patients’ quality of life due to its chronic nature and the fact that a considerable proportion of patients have no response or no sustainable response to current treatments.

Our clinical development our endolysin aims to give CTCL patients a treatment option with a completely new mode of action compared to existing therapies.

  • Specifically targets and kills S. aureus on the skin without a very low propensity for resistance development
  • Improves outcomes for patients by treating skin symptoms and reducing tumor progression
  • Allows for long-term treatment of skin lesions with the potential to reduce infection complications
  • Is well tolerated

We anticipate its use as a topical treatment of the inflammatory skin symptoms associated with CTCL and for the reduction of disease activity and tumor load in adult patients with CTCL.

Prevalence of this incurable, orphan malignancy in the US in 2022 is estimated to be 64,690.

CTCL body

We welcome collaboration with partners who share our ambition, please contact Trine Ahlgreen:

AD header

Atopic Dermatitis (AD)

Colonization of the skin with Staphylococcus aureus (S. aureus) in people with Atopic Dermatitis (AD) plays a significant role in the pathophysiology and severity of the condition. S. aureus produces virulence factors which contribute towards inflammation, skin barrier dysfunction, pruritus, and increased risk of infection.

Due to the chronic nature of the disease AD has a significant long-term impact on quality of life of patients in health-related aspects such as physical, psychosocial, and mental functioning. This means it is imperative to have treatments which are well tolerated and can be used long-term.

Micreos endolysin is first-in-class with a completely new mode of action to existing therapies. Through our clinical development we want to give all AD patients a treatment option which:

  • Kills S. aureus, including resistant strains, while leaving the rest of the microbiome intact
  • Can be used long-term to help control their disease
  • Is well tolerated

With these benefits, our endolysin has the potential to be used across the treatment paradigm – for treatment of flares and as maintenance to prevent flares – in people with mild, moderate or severe AD.

In a meta-analysis, the pooled prevalence of S. aureus colonization among patients was 70% for lesional skin.

We welcome collaboration with partners who share our ambition, please contact Trine Ahlgreen: